An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK) (RANGER-BTK)
An Efficacy and Safety Study to Evaluate Ranger Drug-eluting Balloon for Below the Knee Angioplasty in Patients With Critical Limb Ischemia
Sponsor: Assistance Publique - Hôpitaux de Paris
Listed as NCT02856230, this PHASE2/PHASE3 trial focuses on Lower Limb Ischemia and Peripheral Vascular Diseases and remains ongoing. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jun 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
- Boston Scientific Corporation
For direct contact, visit the study record on ClinicalTrials.gov .